CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders

Frontiers in Neurology

Volumn 6, Issue MAY, 2015, Pages

  Herbert, Megan K ^a,b   Aerts, Marjolein B ^a,c   Beenes, Marijke ^a,b   Norgren, Niklas ^d   Esselink, Rianne A J ^a,c   Bloem, Bastiaan R ^a,c   Bea Kuiperij, H ^a,b   Verbeek, Marcel M ^a,b,c  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Parkinson Center   (Netherlands)

^d UmanDiagnostics AB   (Sweden)

Author keywords

Cerebrospinal fluid; FLT3 ligand; Multiple system atrophy; Neurofilament light chain; Parkinson's disease

Indexed keywords

FLT3 LIGAND; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOSKELETON; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; MAJOR CLINICAL STUDY; MALE; MICROTUBULE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RATING SCALE; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDATION PROCESS;

EID: 84930220495     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00091     Document Type: Article

References (38)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol (2006) 5(6):525-35. doi: 10.1016/S1474-4422(06)70471-9.
2. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 8(12):1128-39. doi:10.1016/S1474-4422(09)70293-5.
3. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol (2008) 15:14-20. doi:10.1111/j.1468-1331.2008.02056.x.
4. Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol (2009) 8(12):1172-8. doi:10.1016/S1474-4422(09)70288-1.
5. Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Köllensperger M, et al. Health-related quality of life in multiple system atrophy. Mov Disord (2006) 21(6):809-15. doi:10.1002/mds.20808.
6. Flabeau O, Meissner WG, Tison F. Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord (2010) 3(4):249-63. doi:10.1177/1756285610375328.
7. Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, et al. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics (2015) 14(3):544-55. doi:10.1074/mcp.M114.040576.
8. Silajdžic E, Constantinescu R, Holmberg B, Björkqvist M, Hansson O. Flt3 ligand does not differentiate between parkinsonian disorders. Mov Disord (2014) 29(10):1319-22. doi:10.1002/mds.25948.
9. Lasec R. Studying the intrinsic determinants of neuronal form and function. In: Lasec RJ, Black MM, editors. Intrinsic Determinants of Neuronal Form and Function. New York, NY: Alan R. Liss Inc (1988). p. 1-60.
10. Vandrovcova J, Pittman AM, Malzer E, Abou-Sleiman PM, Lees AJ, Wood NW, et al. Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease. Neurobiol Aging (2009) 30(9):1477-82. doi:10.1016/j.neurobiolaging.2007.11.019.
11. Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jørgensen HL, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord (2012) 18(1):69-72. doi:10.1016/j.parkreldis.2011.08.012.
12. Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 69(11):1445-52. doi:10.1001/archneurol.2012.1654.
13. Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord (2010) 16(2):142-5. doi:10.1016/j.parkreldis.2009.07.007.
14. Abdo WF, Bloem BR, Van Geel WJ, Esselink RAJ, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging (2007) 28(5):742-7. doi:10.1016/j.neurobiolaging.2006.03.010.
15. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 125(4):861-70. doi:10.1093/brain/awf080.
16. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 71(9):670-6. doi:10.1212/01.wnl.0000324625.00404.15.
17. Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, et al. Ancillary investigations to diagnose parkinsonism: a prospective clinical study. J Neurol (2015) 262(2):346-56. doi:10.1007/s00415-014-7568-4.
18. Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord (2007) 13(8):480-2. doi:10.1016/j.parkreldis.2007.02.002.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology (2001) 57(10):S11-26.
20. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information (1987). p. 153-63.
21. Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci (1997) 145(2):205-11. doi:10.1016/S0022-510X(96)00231-6.
22. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop*. Neurology (1996) 47(1):1-9. doi:10.1212/WNL.47.1.1.
23. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 54(S5):S15-9. doi:10.1002/ana.10570.
24. Brazel CY, Ducceschi MH, Pytowski B, Levison SW. The FLT3 tyrosine kinase receptor inhibits neural stem/progenitor cell proliferation and collaborates with NGF to promote neuronal survival. Mol Cell Neurosci (2001) 18(4):381-93. doi:10.1006/mcne.2001.1033.
25. Shurin MR, Esche C, Lotze MT. FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev (1998) 9(1):37-48. doi:10.1016/S1359-6101(97)00035-X.
26. Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol Scand (2006) 114(3):205-9. doi:10.1111/j.1600-0404.2006.00704.x.
27. Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MV. Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature (1996) 383(6602):716-9. doi:10.1038/383716a0.
28. Mutoh T, Tokuda A, Miyadai T, Hamaguchi M, Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc Natl Acad Sci U S A (1995) 92(11):5087-91. doi:10.1073/pnas.92.11.5087.
29. Chaturvedi RK, Shukla S, Seth K, Agrawal AK. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neurosci Lett (2006) 398(1-2):44-9. doi:10.1016/j.neulet.2005.12.042.
30. Reijn T, Abdo W, Schelhaas H, Verbeek M. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol (2009) 256(4):615-9. doi:10.1007/s00415-009-0131-z.
31. Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of parkinsonian syndromes. Parkinsonism Relat Disord (2001) 8(1):23-31. doi:10.1016/S1353-8020(00)00083-3.
32. Li X-Q, Li L, Xiao C-H, Feng Y-M. NEFL mRNA expression level is a prognostic factor for early-stage breast cancer patients. PLoS One (2012) 7(2):e31146. doi:10.1371/journal.pone.0031146.
33. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res (1992) 52(19):5368-72.
34. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 9(3):131-40. doi:10.1038/nrneurol.2013.10.
35. Kang J, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid β-amyloid 1-42, t-tau, p-tau181, and α-synuclein levels with clinical features of drug-naive patients with early parkinson disease. JAMA Neurol (2013) 70(10):1277-87. doi:10.1001/jamaneurol.2013.3861.
36. Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord (2014) 29(8):1019-27. doi:10.1002/mds.25772.
37. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 69(3):570-80. doi:10.1002/ana.22311.
38. Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat Disord (2014) 20(4):382-7. doi:10.1016/j.parkreldis.2014.01.011.